Alan Brisendine

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors

Carolyn D. Britten, Elizabeth Garrett‐Mayer, Steven Chin et al. · Clinical Cancer Research · 2017 · 165 citations · Full text

Medicine, Oncology, Pharmacology +11

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma

Melanie B. Thomas, Elizabeth Garrett‐Mayer, Munazza Anis et al. · Oncology · 2018 · 48 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder.

Uma Chaudhary, Ali Golshayan, Alan Brisendine et al. · Journal of Clinical Oncology · 2011 · 18 citations

Medicine, Oncology, Urology +16